Stoke Therapeutics (STOK) News Today $25.04 -0.66 (-2.57%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$25.04 0.00 (-0.02%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Stoke Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on ThursdayOctober 24 at 1:41 AM | americanbankingnews.comStoke Therapeutics (STOK) Projected to Announce Earnings on ThursdayOctober 24 at 1:40 AM | marketbeat.comStoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesOctober 22 at 8:36 AM | finance.yahoo.comSTOK - Stoke Therapeutics, Inc.October 20, 2026 | seekingalpha.comStoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.9% - Time to Buy?October 20, 2026 | marketbeat.comReviewing ImageneBio (NASDAQ:IMA) & Stoke Therapeutics (NASDAQ:STOK)October 20, 2026 | americanbankingnews.comStoke Therapeutics: The Market Misread A Key FDA WinOctober 19, 2026 | seekingalpha.comAssenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOKOctober 18, 2026 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Target Price of $44.25 According to BrokeragesOctober 18, 2026 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25October 18, 2026 | marketbeat.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)October 16, 2026 | businesswire.comStoke Therapeutics, Inc. Presents Data Supporting Disease-Modifying Potential Of STK-002 In Autosomal Dominant Optic Atrophy At The American Academy Of Ophthalmology 2026 ...October 13, 2026 | marketscreener.comMAnalysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)October 13, 2026 | theglobeandmail.comStoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?October 13, 2026 | marketbeat.comStoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO ...October 12, 2026 | finance.yahoo.comFDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)October 10, 2026 | finance.yahoo.comStoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual MeetingOctober 6, 2026 | marketscreener.comMStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...October 6, 2026 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?October 6, 2026 | marketbeat.comStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingOctober 6, 2026 | businesswire.comStoke Therapeutics, Inc. Announces Completion Of Successful Meeting With The FDA To Align On Planned U.S. NDA For ZorevunersenOctober 5, 2026 | marketscreener.comMStoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDAOctober 5, 2026 | finance.yahoo.comStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of ...October 5, 2026 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells 627 Shares of StockOctober 3, 2026 | insidertrades.comStoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 SharesOctober 2, 2026 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of StockOctober 2, 2026 | marketbeat.comBank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOKSeptember 27, 2026 | marketbeat.comStoke Therapeutics, Inc. Announces Board ChangesSeptember 23, 2026 | marketscreener.comMStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval ...September 23, 2026 | marketscreener.comMStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and CommercializationSeptember 23, 2026 | businesswire.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 | businesswire.comStoke Therapeutics (NASDAQ:STOK) Insider Sells 5,545 Shares of StockSeptember 4, 2026 | insidertrades.comStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of ...September 3, 2026 | markets.businessinsider.comStoke Therapeutics Inc 0GTSeptember 1, 2026 | morningstar.comMStoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congressSeptember 1, 2026 | msn.comStoke Therapeutics shares rise as JPMorgan starts coverage with Overweight ratingAugust 21, 2026 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,861 SharesAugust 19, 2026 | insidertrades.comStoke Therapeutics (STOK) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comStoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 7, 2026 | seekingalpha.comBarry Ticho Sells 7,176 Shares of Stoke Therapeutics (NASDAQ:STOK) StockAugust 6, 2026 | insidertrades.comStoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 AdvancementAugust 5, 2026 | seekingalpha.comStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth ConferenceAugust 5, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)August 5, 2026 | theglobeandmail.comStoke Therapeutics, Inc. Q2 2026 Earnings Call SummaryAugust 5, 2026 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Q2 2026 EarningsAugust 4, 2026 | 247wallst.comStoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028August 4, 2026 | seekingalpha.comStoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call TranscriptAugust 4, 2026 | seekingalpha.comStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 3, 2026 | businesswire.comStoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial UpdatesJuly 27, 2026 | finance.yahoo.comStoke Therapeutics (STOK) Receives a Buy from JefferiesJuly 24, 2026 | theglobeandmail.com Stoke Therapeutics Media Mentions By Week Stoke Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.480.46▲Average Healthcare News Sentiment Stoke Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼104▲STOK Articles Average Week Stoke Therapeutics Trends on MarketBeatThis week vs. last weekSearches1Page Views2,443-9% Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IOVA News KNSA News RYTM News LGND News IMVT News KOD News CGON News GRAL News MIRM News GRFS News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Stoke Therapeutics dated 10/24/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | SponsoredThe data center backlash is creating a rare investing opportunityA new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
